Urge your members of Congress to support continued medical research funding
After Congress repeatedly failed to pass legislation to
repeal and replace the Affordable Care Act (ACA), President Trump used the
power of the executive branch to make two significant changes to the law, both
of which could have a substantial impact on access to care.
ASH submitted comments to the NIH on hematology-related pediatric research that should be included in the NIH's All of Us research program.
After spending months crafting legislation to repeal and
replace the Affordable Care Act (ACA), in late July, the U.S. Senate had its
chance to vote on and pass repeal legislation.
The National Center for Advancing Translational Sciences (NCATS) released a request for information soliciting input on the use of viral vectors as platforms for therapeutic gene delivery to specific organs or cell types, and how such platforms might be developed most efficiently in clinical trials for the treatment of multiple diseases.
On July 13, 2017, the U.S. Senate released an updated
version of the Better Care Reconciliation Act (BCRA), legislation to repeal
large provisions of the Affordable Care Act (ACA).
Your elected officials need to hear from you about the importance of the Prevention and Public Health Fund.
The House of Representatives released legislation, titled the “American Health Care Act,” to repeal the Affordable Care Act. As written, ASH has serious concerns that this legislation will reduce overall access to coverage and treatment and would greatly impact patients with hematologic diseases and disorders.
Through a notice on its website, the Drug Enforcement Administration (DEA) recently announced significant changes to its registration renewal process. Effective January 1, 2017, the DEA is eliminating the informal grace period which the agency has previously allowed for registrants to renew their registrations.
On December 15, 2016, the Centers for Medicare and Medicaid Services (CMS) announced the cancellation of Medicare Part B Drug Payment Model. CMS initially proposed the demonstration on March 8, 2016 to test new models in how physician-administered drugs are paid under the Medicare program.
ASH is pleased to see the National Heart, Lung and Blood Institute’s (NHLBI) continuous support (RFA-HL-15-030) for the development of improved techniques to enhance the production of clinically relevant, functional stem cell-derived red blood cells or platelets.
Join the Grassroots Network to stay up to date on all of ASH’s Advocacy Campaigns.
Become an advocate for hematology with our easy-to-use advocacy resources.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology